Showing results (181-190 of 198) with videos related to

Sort By:
Pageof 20
Oncology Letters|August 22, 2024
Periprostatic adipose tissue inhibits tumor progression by secreting apoptotic factors: A natural barrier induced by the immune response during the early stages of prostate cancerI-Hung Shao, Tzu-Hsuan Chang, Ying-Hsu Chang, et al.
The Prostate|July 1, 2021
Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro studyDong-Yi Chen, Po-Jung Su, Lai-Chu See, et al.
Neoplasia (New York, N.Y.)|November 14, 2025
Oral bioavailable ITRI-148 degrades androgen receptor variants and overcomes antiandrogen resistance in advanced prostate cancerChiu-Lien Hung, Wen-Ning Hsu, Tsan-Chun Wang, et al.
World Journal of Urology|March 14, 2024
Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert networkAxel S Merseburger, Ganesh Bakshi, Dong-Yi Chen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2022
FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA ExpressionCora N Sternberg, Daniel P Petrylak, Joaquim Bellmunt, et al.
JHEP Reports : Innovation in Hepatology|February 2, 2026
Genome-wide association study identifies three PNPLA3/SAMM50 SNPs associated with HCC development in non-viral liver diseaseXia-Rong Liu, Tsai-Hsuan Yang, Tung-Hung Su, et al.
Asia-Pacific Journal of Clinical Oncology|February 8, 2022
Managing advanced prostate cancer in the Asia Pacific region: "Real-world" application of Advanced Prostate Cancer Consensus Conference 2019 statementsEdmund Chiong, Declan G Murphy, Nicholas C Buchan, et al.
International Journal of Cancer|November 8, 2022
Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancerHung-Kai Chen, Po-Jung Su, Yan-Lin Wang, et al.
NPJ Genomic Medicine|February 5, 2025
Polygenic height prediction for the Han Chinese in TaiwanChih-Hao Chang, Che-Yu Chou, Timothy G Raben, et al.
Acta Cardiologica Sinica|May 26, 2025
Taiwan Consensus for the Management of Cardiovascular Risks and Complications in Patients with Prostate CancerWei-Ting Chang, Jiang-Huang Hong, Dong-Yi Chen, et al.
Pageof 20